Current report filing


Feb. 18, 2022
Cover [Abstract]  
Entity Registrant Name ZIVO BIOSCIENCE, INC.
Entity Central Index Key 0001101026
Document Type 8-K/A
Amendment Flag true
Entity Emerging Growth Company false
Document Period End Date Feb. 18, 2022
Entity Incorporation State Country Code NV
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity File Number 000-30415
Entity Tax Identification Number 87-0699977
Entity Address Address Line 1 21 East Long Lake Road
Entity Address Address Line 2 Suite 100
Entity Address City Or Town Bloomfield Hills
Entity Address State Or Province MI
Entity Address Postal Zip Code 48304
Local Phone Number 452-9866
City Area Code 248
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol ZIVO
Security Exchange Name NASDAQ
Amendment Description This Current Report on Form 8-K/A (“Amendment No. 1”) amends the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 25, 2022 (the “Initial Filing”) by Zivo Bioscience, Inc. (the “Company”). This Amendment No. 1 is being filed pursuant to Item 5.02(a)(3)(iii) of Form 8-K in order to file as an exhibit an email received from Andrew Dahl (“Dahl”), a former member of the Board of Directors of the Company (the “Board”), pursuant to the opportunity to respond to the Initial Filing granted to him under Item 5.02(a)(3)(ii) of Form 8-K. The information contained in this Amendment No. 1 supplements the information contained in the Initial Filing.